Metoprolol Succinate (Beta-blocker)
Treatment for Hypertensive heart disease
Typical Dosage: 25mg - 200mg daily
Effectiveness
85%
Safety Score
70%
Clinical Trials
1,000
Participants
400K
Comparative Safety Scale(Higher is safer)
Cyanideβ οΈ
Methπ
Cigarettesπ¬
Chemoβ’οΈ
AlcoholπΊ
Morphineπ
Antibioticsπ
Tylenolπ
Exerciseπ
Waterπ§
70
DangerousModerateSafe
Treatment Details
Dosage Range
25mg - 200mg daily
Time to Effect
1-2 weeks for full BP effect, months for cardiac remodeling
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
12(Treat 12 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$50
Monitoring:$300
Side Effect Mgmt:$75
Total Annual:$425
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$18,000/QALY
QALYs Gained
2.2
Outcome-Based Costs
Cost per Responder
$607.14
Comparison vs Lisinopril (ACE Inhibitor)
Cost Difference
+$20/year
More expensive
QALY Difference
-0.05 QALYs
Worse outcomes
Dominance
No dominance
Metoprolol Succinate (Beta-blocker) Outcomes
for Hypertensive heart disease
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+70%
Common Side Effects
Fatigue/weakness
+10%
Bradycardia
+5%
Dizziness
+5%
Erectile dysfunction
+10%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov